Company intelligence / Profile preview

Scenic Biotech

Amsterdam, Netherlandsscenicbiotech.com ↗
Ownership
Private
Employees
~50
Development stage
Preclinical
01

Overview

Scenic Biotech has demonstrated positive preclinical results for its lead QPCTL inhibitor SC‑2882 in diffuse large B-cell lymphoma models, showing anti-tumor activity and immune modulation. Three additional programs targeting rare genetic disorders are advancing toward IND-enabling studies. The company’s proprietary Cell-seq platform underpins a robust pipeline of first-in-class small molecule therapies based on the concept of genetic modifier intervention.

Therapeutic areas
OncologyRare DiseasesMetabolic Disorders
Modalities
Small moleculesGenetic modifiers/modifier therapy
Industry
Biotech
02

Drug pipeline

7 assets

SC-2882

Preclinical

6 more assets in the full pipeline.

03

Partnerships

Genentech/Roche – multi-year collaboration on target discovery/development using Cell-seq platform; expanded twice since inception in September 2020.Bristol Myers Squibb – research collaboration announced April 2024 focused on drug target identification for indication selection/expansion using Cell-seq technology.

Beyond the preview

Go deeper on Scenic Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Scenic Biotech.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call